摘要
目的制备风引汤冻干粉,体外评价其抗氧化活性,同时测定风引汤中13种无机元素,建立其特征图谱。方法通过ABTS^(+)、DPPH、OH自由基综合评价风引汤抗氧化能力,采用微波消解法结合电感耦合等离子体原子发射光谱(ICP-OES)及电感耦合等离子体质谱(ICP-MS)测定风引汤中13种无机元素的含量,并绘制无机元素特征图谱。结果风引汤对ABTS^(+)、DPPH两种自由基清除率较强,FRAP均值为2.0535 mmol/mg FeSO_(4);风引汤中含量较高的无机元素有K、Mg、Na、Ca、Zn,无机元素特征图谱具有相似的峰形,不同元素量的多寡顺序趋于一致。Pb、Cd、As、Hg、Cu 5种重金属及有害元素含量均符合《中国药典》2020年版规定的限度要求。结论风引汤具有一定清除自由基的能力,研究有助于其药效机制的阐明,初步明确了风引汤的无机元素组成,同时为风引汤的质量控制研究和安全性评价奠定基础。
Objective To prepare Fengyin Decoction(FYD)freeze-dried powder,evaluated its antioxidant activity in vitro,and determined 13 kinds of inorganic elements in FYD at the same time,and established its characteristic map.Methods The antioxidant capacity of FYD was evaluated comprehensively by ABTS+,DPPH and OH free radicals.The content of 13 inorganic elements in FYD were determined by means of microwave digestion combined with inductively coupled plasma(ICP)-optical emission spectrometer-mass spectrometry(ICP-OES/ICP-MS),and to draw a characteristic spectrum of inorganic elements.Results FYD had a strong scavenging rate for ABTS+and DPPH free radicals.The average iron reduction antioxidant activity(FRAP)value of FYD was 2.0535 mmol/mg FeSO_(4).The high content of inorganic elements in FYD were K,Mg,Na,Ca,and Zn.The characteristic spectrum of inorganic elements had similar peak shapes,and the amount of inorganic elements content in different order tends to be consistent.The content of five heavy metals and harmful elements of Pb,Cd,As,Hg and Cu met the limit requirements of Chinese Pharmacopoeia(2020 edition).Conclusion FYD had a certain ability to scavenge free radicals.This study initially clarified the composition of the inorganic elements of FYD,which was helpful to the elucidation of its pharmacodynamic mechanism and laid the foundation for the quality control research and safety evaluation of FYD.
作者
兰济乐
阮叶萍
尤丽艳
童晓岚
陈忠
LAN Ji-le;RUAN Ye-ping;YOU Li-yan;TONG Xiao-lan;CHEN Zhong(College of Pharmaceutical Science,Zhejiang Chinese Medical University,Hangzhou 310053,China;Zhejiang Key Laboratory of Neuropharmacology and Translational Research,Hangzhou 310053,China)
出处
《时珍国医国药》
CAS
CSCD
北大核心
2022年第2期257-261,共5页
Lishizhen Medicine and Materia Medica Research
基金
国家自然科学基金(81641139)
浙江省自然科学基金(LY20H280004)
浙江中医药大学横向课题(2020-HT-787)。